Novartis Ag (NVS) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $3.2 billion.
- Novartis Ag's Income from Continuing Operations fell 203.96% to $3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $16.4 billion, marking a year-over-year increase of 1988.27%. This contributed to the annual value of $14.0 billion for FY2025, which is 1698.63% up from last year.
- Latest data reveals that Novartis Ag reported Income from Continuing Operations of $3.2 billion as of Q4 2025, which was down 203.96% from $4.2 billion recorded in Q3 2025.
- Over the past 5 years, Novartis Ag's Income from Continuing Operations peaked at $17.0 billion during Q4 2021, and registered a low of $1.6 billion during Q3 2023.
- In the last 5 years, Novartis Ag's Income from Continuing Operations had a median value of $3.2 billion in 2024 and averaged $3.7 billion.
- As far as peak fluctuations go, Novartis Ag's Income from Continuing Operations skyrocketed by 56240.72% in 2021, and later tumbled by 9074.39% in 2022.
- Over the past 5 years, Novartis Ag's Income from Continuing Operations (Quarter) stood at $17.0 billion in 2021, then tumbled by 90.74% to $1.6 billion in 2022, then surged by 51.5% to $2.4 billion in 2023, then soared by 38.2% to $3.3 billion in 2024, then decreased by 2.04% to $3.2 billion in 2025.
- Its Income from Continuing Operations stands at $3.2 billion for Q4 2025, versus $4.2 billion for Q3 2025 and $4.5 billion for Q2 2025.